As weight‑loss drugs surge in popularity, a study raises a new question about what patients may be losing along the way.

By Nancy Lapid April 16 (Reuters) - Eli Lilly's GLP-1 drug tirzepatide yields greater weight loss on average than Novo ...

The study found 4% of users reported "menstrual irregularities," according to Neil Sehgal, the study's first author.

Weight-loss drugs may eventually reach only about 50% of the overweight and obese people who could benefit from them due to ...

More patients on Eli Lilly’s tirzepatide lost over 5% of their lean mass versus those on Novo Nordisk’s semaglutide, ...

A study in Nature found a specific genetic variant that may boost the effectiveness of GLP-1 weight-loss drugs like ...

A new approach to weight loss research is challenging one of the biggest assumptions behind popular weight loss drugs: Are ...

A new UNC School of Medicine study of incretin-based medications, including newer medications such as semaglutide and ...

If you've been watching her lately, you may have noticed that WWE Superstar Rhea Ripley has slimmed down and lost weight ...